Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05051722
Other study ID # 20-012833
Secondary ID NCI-2022-10826
Status Recruiting
Phase
First received
Last updated
Start date August 3, 2021
Est. completion date December 30, 2025

Study information

Verified date May 2024
Source Mayo Clinic
Contact Maureen A Lemens, BSN
Phone 507-293-1487
Email lemens.maureen@mayo.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma and tampon-collected vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.


Description:

Detection of endometrial, ovarian, and cervical cancers at an early stage vastly increases the chances of cure and may also avert morbidity secondary to surgical staging, radiation, and/or chemotherapy. Despite the great successes of cervical cancer screening, comparable early detection methods for other gynecologic cancers and their precursors are not available. While nearly 1.5 million women per year in the United States are evaluated for abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB), the most common symptom of endometrial cancer, most undergo an invasive diagnostic biopsy with the finding of benign etiology. Vaginal bleeding is often the only presenting symptom of women ultimately diagnosed with endometrial cancer (EC) or its precursor lesion, endometrial hyperplasia(EH). More than 90% of women with EC present with vaginal bleeding. Cervical cancer and cervical dysplasia can present as intermenstrual bleeding, post-coital bleeding, or other abnormal vaginal bleeding. However, most women who present with AUB or PMB have a benign etiology. There are approximately 70 million women ≥45 years of age in the United States based on the most recent census data. Between 4-11% of women will be worked up for perimenopausal AUB or PMB in their lifetime. As only 5-10% of those women will have an EC or EH, there is a great clinical need for a less invasive clinical diagnostic test that can reliably distinguish between benign uterine bleeding and bleeding associated with an underlying endometrial cancer, cervical cancer, or a precursor lesion.


Recruitment information / eligibility

Status Recruiting
Enrollment 2640
Est. completion date December 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria for Cohort 1: Women will be =45 years of age and meet at least one of the following criteria: - Abnormal uterine bleeding - Postmenopausal bleeding Exclusion Criteria for Cohort 1: - Prior hysterectomy - Current known pregnancy diagnosis - Any prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia - Current biopsy-proven endometrial cancer or endometrial hyperplasia - - - Current biopsy-proven benign endometrial polyp - Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium Inclusion Criteria for Cohort 2: Women will be =18 years of age and meet at least one of the following criteria: - Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection - Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc) Exclusion Criteria for Cohort 2: - Undergoing surgical procedure for recurrent or metastatic EC - Receipt of preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven cervical cancer - Presence of concomitant biopsy-proven cervical dysplasia - Any prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 3: Women will be =18 years of age, have a cervix and meet at least one of the following criteria: - History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy - Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated - Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible) Exclusion Criteria for Cohort 3: - History of pelvic or vaginal radiotherapy - Prior total hysterectomy (cervix removed) for any indication - Current known pregnancy diagnosis - Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 4: Women will be =45 years of age and should meet at least one of the following criteria: - Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps. - Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed. Exclusion Criteria for Cohort 4: - Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis - Any surgery within the past 3 months - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven gynecologic cancer - Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia - Prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis - Prior intervention or surgery with intent to completely remove the target pathology Inclusion Criteria for Cohort 5: Women will be =45 years of age and should meet the following criteria: - Presenting for well-woman exam, ± Pap test - No change in medical conditions, new diagnoses, or new medications within the past 6 months; Exclusion Criteria for Cohort 5: - Pap test or cervical biopsy within the past 1 month - Endometrial biopsy or office hysteroscopy within the past 1 month - Any surgery within the past 3 months - Prior hysterectomy - Current known pregnancy diagnosis - Prior or current biopsy-proven gynecologic cancer - Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia - Prior pelvic or vaginal radiotherapy - Any prior cancer (except basal cell skin cancer) within the past 5 years - Chemotherapy within the past 5 years - Criteria met for inclusion in any of the other study cohorts Inclusion Criteria for Cohort 6: Women =50 years of age and: - Postmenopausal status - At least 1 intact ovary - Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer) - Planned surgery for the adnexal mass - For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion) Exclusion criteria - Isolated Adnexal Mass cohort: (Cohort 6) - Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) - Chemotherapy for cancer treatment within the past 5 years prior to collection - Clinically-suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection - Surgical candidates for recurrent ovarian cancer - History of pelvic or vaginal radiation therapy - Known current synchronous endometrial cancer or hyperplasia - Known current cervical, vaginal, or vulvar dysplasia Inclusion criteria - OC Cohort: (Cohort 7) Women will be =18 years of age and meet the following criteria: - Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology - Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy - At least one intact ovary - For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion) Exclusion criteria - OC Cohort (Cohort 7): - Patients with recurrent OC - Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years - Chemotherapy for cancer treatment within the past 5 years prior to collection - History of pelvic or vaginal radiation therapy - Known current synchronous endometrial cancer or hyperplasia - Known current cervical, vaginal, or vulvar dysplasia

Study Design


Intervention

Diagnostic Test:
Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Locations

Country Name City State
United States University of Chicago Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States Providea Health Partners, LLC Evergreen Park Illinois
United States Altru Health System Grand Forks North Dakota
United States The Woman's Health Pavilion Howard Beach New York
United States University of Mississippi Medical Center Jackson Mississippi
United States Mayo Clinic Jacksonville Florida
United States Medical Colleagues of Texas, LLP Katy Texas
United States Genoma Research, Inc. Miami Florida
United States My GYN Care Miami Florida
United States Signature Women's Healthcare, LLC Pembroke Pines Florida
United States Mayo Clinic Phoenix Arizona
United States Mayo Clinic Rochester Minnesota
United States Valley OB-GYN Clinic Saginaw Michigan
United States Sarasota Memorial Health Care System Sarasota Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within tampon-collected vaginal fluid in a larger, more diverse cohort. Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development. 18 months
Primary Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within tampon-collected vaginal fluid and plasma in a larger, more diverse cohort. Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development. 18 months
Secondary Using 95% specificity cutoffs of the final tampon-based MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test. 18 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2

External Links